{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:53:17Z","timestamp":1785873197552,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9-10","license":[{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The use of mesenchymal stem cells is considered a\u00a0novel and promising therapeutic option for patients with perianal fistulizing Crohn\u2019s disease; however, data on its clinical application remain scarce. This multicenter nationwide study aimed to assess the clinical efficacy of mesenchymal stem cells in closing complex anal fistulas.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this study 14 Crohn\u2019s disease patients (3\u00a0males, 11\u00a0females) with complex anal fistulas treated in 3 tertiary hospitals in Austria were included between October 2018 and April 2021.<\/jats:p>\n                <jats:p>Injection of 120 million allogeneic expanded adipose-derived mesenchymal stem cells (Cx601\u2014darvadstrocel) was performed in each patient. Closure of the external fistula opening without secretion by external manual compression was defined as treatment success.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median age of the patient population at the time of surgery was 32\u00a0years (range 26\u201353\u00a0years) with a\u00a0median body mass index of 21.7\u202fkg\/m<jats:sup>2<\/jats:sup> (range 16.7\u201326.6\u202fkg\/m<jats:sup>2<\/jats:sup>). Of the patients 12 (86%) received monoclonal antibodies (infliximab, adalimumab, ustekinumab, vedolizumab) at the time of surgery.<\/jats:p>\n                <jats:p>The median number of complex fistulas was 1.4 (range 1\u20132), The median operative time was 20\u202fmin (range 6\u201350\u202fmin) with no perioperative complications.<\/jats:p>\n                <jats:p>After a\u00a0median follow-up of 92\u00a0weeks, we found successful fistula closure in 57.1% (<jats:italic>n<\/jats:italic>\u202f=\u20098) of treated patients. The perianal disease activity index did not improve significantly from initially 7 to a\u00a0median of 6 after 52\u00a0weeks (<jats:italic>p<\/jats:italic>\u202f=\u20090.495).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Darvadstrocel is a\u00a0safe, minimally invasive surgical technique without significant perioperative complications. Clinical success can be expected in about half of the treated patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00508-023-02283-4","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T15:01:56Z","timestamp":1697122916000},"page":"289-294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn\u2019s disease\u2014A\u00a0prospective nationwide multicenter cohort study"],"prefix":"10.1007","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1432-2804","authenticated-orcid":false,"given":"Christopher","family":"Dawoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin Melanie","family":"Widmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Czipin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pramhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Scharitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Stift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Harpain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Riss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,12]]},"reference":[{"issue":"4","key":"2283_CR1","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1053\/gast.2002.32362","volume":"122","author":"DA Schwartz","year":"2002","unstructured":"Schwartz\u00a0DA, Loftus\u00a0EV Jr., Tremaine\u00a0WJ, Panaccione\u00a0R, Harmsen\u00a0WS, Zinsmeister\u00a0AR, et\u00a0al. The natural history of fistulizing Crohn\u2019s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122(4):875\u201380.","journal-title":"Gastroenterology"},{"issue":"9","key":"2283_CR2","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1046\/j.1365-2036.2003.01561.x","volume":"17","author":"SJ Bell","year":"2003","unstructured":"Bell\u00a0SJ, Williams\u00a0AB, Wiesel\u00a0P, Wilkinson\u00a0K, Cohen\u00a0RC, Kamm\u00a0MA. The clinical course of fistulating Crohn\u2019s disease. Aliment Pharmacol Ther. 2003;17(9):1145\u201351.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2283_CR3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.7326\/0003-4819-123-2-199507150-00009","volume":"123","author":"DC Pearson","year":"1995","unstructured":"Pearson\u00a0DC, May\u00a0GR, Fick\u00a0GH, Sutherland\u00a0LR. Azathioprine and 6\u2011mercaptopurine in Crohn disease. A\u00a0meta-analysis. Ann Intern Med. 1995;123(2):132\u201342.","journal-title":"Ann Intern Med"},{"issue":"18","key":"2283_CR4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJM198005013021801","volume":"302","author":"DH Present","year":"1980","unstructured":"Present\u00a0DH, Korelitz\u00a0BI, Wisch\u00a0N, Glass\u00a0JL, Sachar\u00a0DB, Pasternack\u00a0BS. Treatment of Crohn\u2019s disease with 6\u2011mercaptopurine. A\u00a0long-term, randomized, double-blind study. N\u00a0Engl J Med. 1980;302(18):981\u20137.","journal-title":"N Engl J Med"},{"issue":"18","key":"2283_CR5","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present\u00a0DH, Rutgeerts\u00a0P, Targan\u00a0S, Hanauer\u00a0SB, Mayer\u00a0L, van Hogezand\u00a0RA, et\u00a0al. Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N\u00a0Engl J Med. 1999;340(18):1398\u2013405.","journal-title":"N Engl J Med"},{"issue":"11","key":"2283_CR6","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1111\/j.1365-2036.2005.02670.x","volume":"22","author":"E Domenech","year":"2005","unstructured":"Domenech\u00a0E, Hinojosa\u00a0J, Nos\u00a0P, Garcia-Planella\u00a0E, Cabre\u00a0E, Bernal\u00a0I, et al. Clinical evolution of luminal and perianal Crohn\u2019s disease after inducing remission with infliximab: how long should patients be treated? Aliment Pharmacol Ther. 2005;22(11):1107\u201313.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"2283_CR7","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1097\/MIB.0000000000000148","volume":"20","author":"I Molendijk","year":"2014","unstructured":"Molendijk\u00a0I, Nuij\u00a0VJ, van der Meulen-de Jong\u00a0AE, van der Woude\u00a0CJ. Disappointing durable remission rates in complex Crohn\u2019s disease fistula. Inflamm Bowel Dis. 2014;20(11):2022\u20138.","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"2283_CR8","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands\u00a0BE, Anderson\u00a0FH, Bernstein\u00a0CN, Chey\u00a0WY, Feagan\u00a0BG, Fedorak\u00a0RN, et\u00a0al. Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N\u00a0Engl J Med. 2004;350(9):876\u201385.","journal-title":"N Engl J Med"},{"issue":"3","key":"2283_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4291\/wjgp.v5.i3.205","volume":"5","author":"M Scharl","year":"2014","unstructured":"Scharl\u00a0M, Rogler\u00a0G. Pathophysiology of fistula formation in Crohn\u2019s disease. World J Gastrointest Pathophysiol. 2014;5(3):205\u201312.","journal-title":"World J Gastrointest Pathophysiol"},{"issue":"4","key":"2283_CR10","doi-asserted-by":"publisher","first-page":"340","DOI":"10.4240\/wjgs.v13.i4.340","volume":"13","author":"P Garg","year":"2021","unstructured":"Garg\u00a0P, Kaur\u00a0B, Goyal\u00a0A, Yagnik\u00a0VD, Dawka\u00a0S, Menon\u00a0GR. Lessons learned from an audit of 1250 anal fistula patients operated at a\u00a0single center: a\u00a0retrospective review. World J Gastrointest Surg. 2021;13(4):340\u201354.","journal-title":"World J Gastrointest Surg"},{"key":"2283_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-pathol-011110-130230","volume":"6","author":"NG Singer","year":"2011","unstructured":"Singer\u00a0NG, Caplan\u00a0AI. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol. 2011;6:457\u201378.","journal-title":"Annu Rev Pathol"},{"issue":"11","key":"2283_CR12","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.3748\/wjg.v21.i11.3330","volume":"21","author":"D Garcia-Olmo","year":"2015","unstructured":"Garcia-Olmo\u00a0D, Guadalajara\u00a0H, Rubio-Perez\u00a0I, Herreros\u00a0MD, de-la-Quintana\u00a0P, Garcia-Arranz\u00a0M. Recurrent anal fistulae: limited surgery supported by stem cells. World J Gastroenterol. 2015;21(11):3330\u20136.","journal-title":"World J Gastroenterol"},{"issue":"10051","key":"2283_CR13","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/S0140-6736(16)31203-X","volume":"388","author":"J Panes","year":"2016","unstructured":"Panes\u00a0J, Garcia-Olmo\u00a0D, Van Assche\u00a0G, Colombel\u00a0JF, Reinisch\u00a0W, Baumgart\u00a0DC, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn\u2019s disease: a\u00a0phase\u00a03 randomised, double-blind controlled trial. Lancet. 2016;388(10051):1281\u201390.","journal-title":"Lancet"},{"key":"2283_CR14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ijsu.2019.11.002","volume":"72","author":"R Agha","year":"2019","unstructured":"Agha\u00a0R, Abdall-Razak\u00a0A, Crossley\u00a0E, Dowlut\u00a0N, Iosifidis\u00a0C, Mathew\u00a0G, et al. STROCSS 2019 guideline: strengthening the reporting of cohort studies in surgery. Int J Surg. 2019;72:156\u201365.","journal-title":"Int J Surg"},{"issue":"7","key":"2283_CR15","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3390\/cells8070764","volume":"8","author":"M Carvello","year":"2019","unstructured":"Carvello\u00a0M, Lightner\u00a0A, Yamamoto\u00a0T, Kotze\u00a0PG, Spinelli\u00a0A. Mesenchymal stem cells for perianal Crohn\u2019s disease. Cells. 2019;8(7):764. https:\/\/doi.org\/10.3390\/cells8070764.","journal-title":"Cells"},{"issue":"9624","key":"2283_CR16","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","volume":"371","author":"K Le Blanc","year":"2008","unstructured":"Le Blanc\u00a0K, Frassoni\u00a0F, Ball\u00a0L, Locatelli\u00a0F, Roelofs\u00a0H, Lewis\u00a0I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a\u00a0phase\u00a0II study. Lancet. 2008;371(9624):1579\u201386.","journal-title":"Lancet"},{"issue":"1","key":"2283_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.stem.2009.05.003","volume":"5","author":"RH Lee","year":"2009","unstructured":"Lee\u00a0RH, Pulin\u00a0AA, Seo\u00a0MJ, Kota\u00a0DJ, Ylostalo\u00a0J, Larson\u00a0BL, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG\u20116. Cell Stem Cell. 2009;5(1):54\u201363.","journal-title":"Cell Stem Cell"},{"key":"2283_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1476-9255-2-8","volume":"2","author":"JM Ryan","year":"2005","unstructured":"Ryan\u00a0JM, Barry\u00a0FP, Murphy\u00a0JM, Mahon\u00a0BP. Mesenchymal stem cells avoid allogeneic rejection. J\u00a0Inflamm. 2005;2:8.","journal-title":"J Inflamm"},{"issue":"1\u20132","key":"2283_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jneuroim.2010.07.013","volume":"227","author":"B Yamout","year":"2010","unstructured":"Yamout\u00a0B, Hourani\u00a0R, Salti\u00a0H, Barada\u00a0W, El-Hajj\u00a0T, Al-Kutoubi\u00a0A, et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a\u00a0pilot study. J\u00a0Neuroimmunol. 2010;227(1\u20132):185\u20139.","journal-title":"J Neuroimmunol"},{"issue":"2","key":"2283_CR20","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1161\/CIRCULATIONAHA.104.527937","volume":"112","author":"W Dai","year":"2005","unstructured":"Dai\u00a0W, Hale\u00a0SL, Martin\u00a0BJ, Kuang\u00a0JQ, Dow\u00a0JS, Wold\u00a0LE, et al. Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short- and long-term effects. Circulation. 2005;112(2):214\u201323.","journal-title":"Circulation"},{"issue":"2","key":"2283_CR21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1365-2249.2007.03422.x","volume":"149","author":"JM Ryan","year":"2007","unstructured":"Ryan\u00a0JM, Barry\u00a0F, Murphy\u00a0JM, Mahon\u00a0BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol. 2007;149(2):353\u201363.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"2283_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0301-472X(01)00769-X","volume":"30","author":"A Bartholomew","year":"2002","unstructured":"Bartholomew\u00a0A, Sturgeon\u00a0C, Siatskas\u00a0M, Ferrer\u00a0K, McIntosh\u00a0K, Patil\u00a0S, et\u00a0al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30(1):42\u20138.","journal-title":"Exp Hematol"},{"issue":"12","key":"2283_CR23","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1182\/blood-2003-11-3909","volume":"103","author":"R Meisel","year":"2004","unstructured":"Meisel\u00a0R, Zibert\u00a0A, Laryea\u00a0M, Gobel\u00a0U, Daubener\u00a0W, Dilloo\u00a0D. Human bone marrow stromal cells inhibit allogeneic T\u2011cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004;103(12):4619\u201321.","journal-title":"Blood"},{"issue":"10","key":"2283_CR24","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1002\/stem.1483","volume":"31","author":"JA Horton","year":"2013","unstructured":"Horton\u00a0JA, Hudak\u00a0KE, Chung\u00a0EJ, White\u00a0AO, Scroggins\u00a0BT, Burkeen\u00a0JF, et al. Mesenchymal stem cells inhibit cutaneous radiation-induced fibrosis by suppressing chronic inflammation. Stem Cells. 2013;31(10):2231\u201341.","journal-title":"Stem Cells"},{"issue":"5","key":"2283_CR25","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00384-003-0490-3","volume":"18","author":"D Garcia-Olmo","year":"2003","unstructured":"Garcia-Olmo\u00a0D, Garcia-Arranz\u00a0M, Garcia\u00a0LG, Cuellar\u00a0ES, Blanco\u00a0IF, Prianes\u00a0LA, et al. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn\u2019s disease: a\u00a0new cell-based therapy. Int J Colorectal Dis. 2003;18(5):451\u20134.","journal-title":"Int J Colorectal Dis"},{"issue":"5","key":"2283_CR26","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2017.12.020","volume":"154","author":"J Panes","year":"2018","unstructured":"Panes\u00a0J, Garcia-Olmo\u00a0D, Van Assche\u00a0G, Colombel\u00a0JF, Reinisch\u00a0W, Baumgart\u00a0DC, et al. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn\u2019s disease. Gastroenterology. 2018;154(5):1334\u201342.e4.","journal-title":"Gastroenterology"},{"issue":"6","key":"2283_CR27","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1111\/codi.15587","volume":"23","author":"D Cabalzar-Wondberg","year":"2021","unstructured":"Cabalzar-Wondberg\u00a0D, Turina\u00a0M, Biedermann\u00a0L, Rogler\u00a0G, Schreiner\u00a0P. Allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulas in Crohn\u2019s disease: a\u00a0case series. Colorectal Dis. 2021;23(6):1444\u201350.","journal-title":"Colorectal Dis"},{"issue":"24","key":"2283_CR28","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.3748\/wjg.v27.i24.3643","volume":"27","author":"O Schwandner","year":"2021","unstructured":"Schwandner\u00a0O. Stem cell injection for complex anal fistula in Crohn\u2019s disease: a\u00a0single-center experience. World J Gastroenterol. 2021;27(24):3643\u201353.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"2283_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/codi.15324","volume":"23","author":"M Nikolic","year":"2021","unstructured":"Nikolic\u00a0M, Stift\u00a0A, Reinisch\u00a0W, Vogelsang\u00a0H, Matic\u00a0A, Muller\u00a0C, et al. Allogeneic expanded adipose-derived stem cells in the treatment of rectovaginal fistulas in Crohn\u2019s disease. Colorectal Dis. 2021;23(1):153\u20138.","journal-title":"Colorectal Dis"},{"issue":"1","key":"2283_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/j.gastro.2017.04.001","volume":"153","author":"AB Dietz","year":"2017","unstructured":"Dietz\u00a0AB, Dozois\u00a0EJ, Fletcher\u00a0JG, Butler\u00a0GW, Radel\u00a0D, Lightner\u00a0AL, et\u00a0al. Autologous mesenchymal stem cells, applied in a\u00a0bioabsorbable matrix, for treatment of perianal fistulas in patients with Crohn\u2019s disease. Gastroenterology. 2017;153(1):59\u201362.e2.","journal-title":"Gastroenterology"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02283-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-023-02283-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02283-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T11:11:59Z","timestamp":1715166719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-023-02283-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,12]]},"references-count":30,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2283"],"URL":"https:\/\/doi.org\/10.1007\/s00508-023-02283-4","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,12]]},"assertion":[{"value":"25 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.\u00a0Dawoud received honoraria for invited presentations during satellite symposia from Takeda. M.\u00a0Scharitzer received honoraria from Takeda for invited presentations during advisory board meetings and satellite symposia. A.\u00a0Stift received honoraria from Takeda for invited presentations. F.\u00a0Harpain reports honoraria from Takeda for invited presentations during satellite symposia. and S.\u00a0Riss received honoraria from Takeda for invited presentations during advisory board meetings and satellite symposia. K.M.\u00a0Widmann, S.\u00a0Czipin and M.\u00a0Pramhas declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the Medical University of Vienna and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}